Gufic Biosciences Reports Robust Q2 FY27 Financial and Operational Performance
Gufic Biosciences Ltd 路 Investor Presentation 路 15 Nov 2026, 2:04 am
Gufic Biosciences Reports Robust Q2 FY27 Financial and Operational Performance Gufic Biosciences posted a total revenue of Rs 288.4 cr in Q2 FY27, up 25.17% YoY from Rs 230.4 cr in Q2 FY26 and 10.58% QoQ. EBITDA reached Rs 49.7 cr with a 17.23% margin, while PAT stood at Rs 23.5 cr (8.15% margin), rising 57.72% YoY. For H1 FY27, total income reached Rs 550.8 cr with PAT of Rs 46.0 cr. Operationally, the US FDA completed a pre-approval inspection at its Indore facility with three observations being addressed, while EU GMP certification remains awaited.
Original exchange filing (PDF)
More announcements from Gufic Biosciences Ltd
- Intimation of Audio Recording of Earnings Conference Call held on November 16, 2026 at 04:30 p.m. is attached herewith 路 17 Nov 2026
- Intimation for appointment of Additional Director (Non-Executive Independent Director) of the Company is attached herewith. 路 15 Nov 2026
- Gufic Biosciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 15 Nov 2026
- Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year Ended September 30, 2026 is attached herewith 路 15 Nov 2026
- Outcome of the Board of Directors Meeting held on Saturday, November 14, 2026 is attached herewith. 路 15 Nov 2026
- Intimation of Environmental, Social and Governance (''ESG'') Rating is attached herewith 路 13 Nov 2026
- Intimation of Earnings Conference Call scheduled to be held on November 16, 2026 is attached herewith 路 16 Nov 2026
- Gufic Biosciences Limited has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business. 路 14 Nov 2026
